Healthcare Industry News: BioGenex
News Release - September 8, 2006
BioGenex Names Medical Technology Executive Raymond W. Cohen to Board of DirectorsSAN RAMON, Calif., Sept. 7 (HSMN NewsFeed) -- BioGenex, Inc., a leading manufacturer of automated diagnostic laboratory instruments for cellular and molecular pathology, announced today that veteran medical technology executive Raymond W. Cohen has been named to its board of directors. The move signals the Company's intention to vigorously explore various financing and strategic options.
BioGenex Chairman Krishan L. Kalra, Ph.D said, "We're confident that we will benefit greatly from Mr. Cohen's operating experience in the medical device industry and proven track record in raising capital, mergers and acquisitions, and strategic alliances. We look forward to Ray's contributions as BioGenex executes on our plan to capitalize on 25 years of technology and intellectual property leadership in the field of immunohistochemistry."
Cohen, 47, an accredited director who has more than 25 years of leadership and entrepreneurial experience in medical technology, currently serves as chief executive officer and director of Laguna Hills, CA-based Symphony Medical, Inc., a venture capital-backed, privately-held developer of biologic solutions for the treatment of cardiac conduction abnormalities.
Cohen also serves as the chairman of the board of directors of Bothell, WA-based Cardiac Science Corporation, a global leader in cardiac monitoring and automatic defibrillation products where Cohen served as chief executive officer for nine years. Cohen is as a member of the board of directors of BioLife Solutions, Inc., a manufacturer of cryopreservation products used for human cell and tissue preservation, based in Owego, NY. In addition, Cohen is a director of Syncroness, Inc., a privately-held contract engineering and product development firm based in Westminster, CO and on the advisory board for the College of Osteopathic Medicine, Western University of Health Sciences in Pomona, CA.
Cohen is a graduate of State University of New York at Binghamton with a degree in business management and is an accredited public company director having completed the certification program at UCLA's Anderson Graduate School of Management.
About BioGenex, Inc.
BioGenex, founded in 1981, is a privately held company that develops manufacturers and markets proprietary automated laboratory instruments that streamline operations in anatomic pathology and provides reagents for the detection and diagnosis of cancer and infectious diseases. BioGenex serves the needs of clinical diagnostics and research laboratories with innovative technologies for cellular and molecular pathology. The Company's customers include reference laboratories, hospital laboratories, cancer treatment centers, university medical centers, large group practices and drug discovery laboratories in pharmaceutical and biotechnology firms.
For more information on BioGenex please visit our website at http://www.BioGenex.com or contact David Sheldon at 925 275-0550 or via email at InvestorRelations@BioGenex.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.